Topiramate for acute affective episodes in bipolar disorder in adults

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Pigott, Katie ^a   Galizia, Ilaria ^a,b   Vasudev, Kamini ^c   Watson, Stuart ^d   Geddes, John ^e   Young, Allan H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Wolfson Research Centre   (United Kingdom)

^e WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; PLACEBO; TOPIRAMATE;

ADJUVANT THERAPY; ADULT; BIPOLAR DISORDER; COCHRANE LIBRARY; COMORBIDITY; DRUG EFFECT; EMBASE; HOSPITAL PATIENT; HUMAN; MEDLINE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

EID: 84985014388     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003384.pub3     Document Type: Review

References (77)

1. Chengappa KN, Schwarzmann LK, Hulihan JF, Xiang J, Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. Neuropsychopharmacology 2005;30(Suppl 1):S235.
2. Chengappa KNR, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 2006;67(11):1698-1706.
3. NCT00237289 Topiramate versus placebo as add-on treatment in patients with bipolar disorder in the outpatient setting. http://www.clinicaltrials.gov/ct2/show/NCT00237289 2006, issue accessed 1 January 2014.
4. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disorders 2001;3(5):215-32.
5. McIntyre R, Mancini DA, McCann SM, Srinavasan J, Sagman D, Kennedy SH. Randomised, single-blind comparison of topiramate and bupropion sr in bipolar depression. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):56.
6. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disorder 2002;4:207-13.
7. McIntyre RS, Mancini DA, McCann SM, Srinivasan J, Sagman D, Kennedy SH. Randomized, single-blind comparison of topiramate and bupropion SR as add-on therapy in bipolar depression. 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000 Dec 10-14; San Juan, Puerto Rico. 149.
8. McIntyre RS, Mancini DA, McCann SM, Srinivasan J, Sagman D, Kennedy SH. Randomized, single-blind comparison of topiramate and bupropion sustained release as add-on therapy in bipolar depression. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans. NR104.
9. McIntyre RS, Mancini DA, McCann SM, Srinivasan J, Sagman D, Kennedy SH. Randomized, single-blind comparison of topiramate and bupropion sustained release as add-on therapy in bipolar depression. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia.
10. McIntyre RS, McCann SM, Mancini DA, Kennedy SH. Randomized, single-blind comparison of topiramate and bupropion SR added to mood stabilizer in bipolar disorder. Acta Neuropsychiatrica 2000;12(3):163.
11. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the managment of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorder 2006;8:15-27.
12. NCT00037674 A randomized, double-blind, multicenter, placebo-controlled 12-week study of the safety and efficacy of two doses of topiramate for the treatment of acute manic or mixed episodes in patients with bipolar I disorder with an optional open-label extension. https://clinicaltrials.gov/ct2/show/NCT00037674 2002, issue accessed 1 January 2014.
13. Power PS, Sachs GS, Kushner SF, Wang D, Olson W, Capece J, et al. Topiramate in adults with acute bipolar I mania. New Research Abstracts, American Psychiatric Association 2004, 157th Annual Meeting, New York, NY, May 1-6, 2004 (Abstract NR 365).
14. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the managment of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorders 2006;8:15-27.
15. NCT00240721 A randomized, double-blind, multicenter, placebo-controlled 12-week study of the safety and efficacy of two doses of topiramate for the treatment of acute manic or mixed episodes in subjects with bipolar I disorder with an optional open-label extension. https://clinicaltrials.gov/ct2/show/NCT00240721 2005, issue accessed 1 January 2014.
16. Power PS, Sachs GS, Kushner SF, Wang D, Olson W, Capece J, et al. Topiramate in adults with acute bipolar I mania. New Research Abstracts, American Psychiatric Association 2004, 157th Annual Meeting, New York, NY, May 1-6, 2004 (Abstract NR 365).
17. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the managment of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorders 2006;8:15-27.
18. Power PS, Sachs GS, Kushner SF, Wang D, Olson W, Capece J, et al. Topiramate in adults with acute bipolar I mania. New Research Abstracts, American Psychiatric Association 2004, 157th Annual Meeting, New York, NY, May 1-6, 2004 (Abstract NR 365).
19. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the managment of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorders 2006;8:15-27.
20. NCT00035230 A randomized, double-blind, multicenter, placebo-controlled 12-week study of the safety and efficacy of topiramate in patients with acute manic or mixed episodes of bipolar I disorder with an optional open-label extension. https://clinicaltrials.gov/ct2/show/NCT00035230 2002, issue accessed 1 January 2014.
21. Power PS, Sachs GS, Kushner SF, Wang D, Olson W, Capece J, et al. Topiramate in adults with acute bipolar I mania. New Research Abstracts, American Psychiatric Association 2004, 157th Annual Meeting, New York, NY, May 1-6, 2004 (Abstract NR 365).
22. Bahk WM, Shin YC, Woo JM, Yoon BH, Lee JS, Jon DI, et al. Effectiveness and tolerability of topiramate versus divalproex in bipolar mania. Korean Journal of Psychopharmacology 2004;15(4):425-32.
23. Bahk WM, Shin YC, Woo JM, Yoon BH, Lee JS, Jon DI, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005;29(1):115-21.
24. DelBello MP, Kushner SF, Wang D, Olson W, Capece J, Fazzio L, et al. Topiramate for acute mania in adolescent patients with bipolar I disorder. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. NR363.
25. Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA, et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2005;44(6):539-47.
26. Hebrani P, Behdani F, Manteghi AA. Double-blind, randomized, clinical trial of topiramate versus sodium valproate for the treatment of bipolar disorder in adolescents. Pakistan Journal of Medical Sciences 2009;25(2):247-52.
27. Mahmoudi-Gharaei J, Shahrivar Z, Faghihi T, Mohammadi MR, Tehrani-Doost M, Alaghband-Rad J, et al. Topiramate versus valproate sodium as adjunctive therapies to a combination of lithium and risperidone for adolescents with bipolar I disorder: effects on weight and serum lipid profile. Iranian Journal of Psychiatry 2012;7(1):1-10. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395968/]
28. McIntyre RS, Riccardelli R, Binder C, Kusumakar V. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. The Canadian Journal of Psychiatry 2005;50(7):415-22.
29. Mirsepassi Z, Mazinani R, Fadai F, Beigi NA, Astaneh AN. Effect of topiramate on weight control in bipolar type I patients receiving lithium and antipsychotics during manic episode. Iranian Journal of Psychiatry and Clinical Psychology 2014;19(3):195-201.
30. IRCT2012061310013N1 Comparison of treatment of bipolar disorder (lithium + olanzapine + clonazepam) and placebo with a treatment regimen containing topiramate in controlling the OCD symptoms of bipolar patients. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2012061310013N1 issue accessed 1 January 2014.
31. Sahraian A, Bigdeli M, Ghanizadeh A, Rezaee V. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder, a randomized double blind placebo controlled clinical trial [abstract]. Bipolar Disorders 2014;96. [IRCT2012061310013N1]
32. Sahraian A, Bigdeli M, Ghanizadeha A, Akhondzadeh S. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. Journal of Affective Disorders 2014;166:201-5.
33. Vieta E, Sánchez-Moreno J, Goikolea JM, Colom F, Martínez-Arán A, Benabarre A, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. Journal of Clinical Psychopharmacology 2004;24(4):374-8.
34. Wozniak J. Olanzapine plus topiramate versus olanzapine plus omega-3 fatty acids for bipolar disorder. http://www.stanleyresearch.org/ 2000, issue accessed 1 January 2014.
35. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of paediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology 2009;19(5):539-45.
36. Calabrese JR. Update on the use of topiramate in bipolar disorder. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago. Vol. No. 44A.
37. Calabrese JR. Update on the use of topiramate in bipolar disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia.
38. Mirsepassi Z, Mazinani R, Fadai F, Alibeigi N, Nazeri-Astaneh A. Topiramate add-on lithium carbonate for treatment of acute mania. Iranian Journal of Psychiatry and Behavioral Sciences 2013;7(2):11-5.
39. Yoon BH, Bae SO, Yoon JS, Kim MK, Sea YW. Combination of topiramate in acute mania. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, CA. NR507.
40. Yoon BH, Bae SO, Yoon JS, Lee KL, Choi Y. Combination of topiramate in acute mania. Korean Journal of Psychopharmacology 2002;13(4):246-53.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
42. Bourgeois BF. New antiepileptic drugs. Archives of Neurology 1998;55(9):1181-3.
43. Cavanagh J, Schwannauer M, Power M, Goodwin GM. A novel scale for measuring mixed states in bipolar disorder. Clinical Psychology & Psychotherapy 2009;16:497-509. [DOI: 10.1002/cpp.633]
44. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
45. Goodwin RK, Jamison KR. Manic-Depressive Illness. Bipolar Disorders and Recurrent Depression. 2nd Edition. Oxford University Press, 2007.
46. Hamilton M. Rating depressive patients. Journal of Clinical Psychiatry 1980;41:21-4.
47. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
48. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the managment of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorders 2006;8:15-27.
50. Macritchie K, Geddes J, Scott J, Haslam DR, Silva de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD004052]
51. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabiliser. Journal of Affective Disorders 1998;50(2-3):245-51.
52. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biological Psychiatry 2000;47(12):1025-33.
53. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37 Suppl 6:S4-11.
54. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archives of General Psychiatry 2011;68(3):241-51. [DOI: 10.1001/archgenpsychiatry.2011.12]
55. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
56. National Institute for Health and Care Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Care Excellence; 2006 July. NICE Clinical Guideline 38.
57. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116(1):78-84.
58. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry 2006;163(2):217-24.
59. Petty F. GABA and mood disorders: a brief review and hypothesis. Journal of Affective Disorders 1995;34:275-81.
60. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. The Lancet 2013;381(9878):1663-71.
61. Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disorders 2012;14:573-84. [DOI: 10.1111/j.1399-5618.2012.01042.x]
62. Power PS, Sachs GS, Kushner SF, Wang D, Olson W, Capece J, et al. Topiramate in adults with acute bipolar I mania. New Research Abstracts, American Psychiatric Association 2004, 157th Annual Meeting, New York, NY, May 1-6, 2004 (Abstract NR 365).
63. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. The Lancet 2007;370(9590):859-77.
64. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
65. Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neuroscience & Therapeutics 2011;17(3):167-77. [DOI: 10.1111/j.1755-5949.2009.00089.x]
66. Sachs G, Koslow GC, Orsini C, Cosgrove V, Sambur M, Demopulous C, et al. Treatment of refractory bipolar mood disorder: efficacy of topiramate. Acta Neuropsychiatrica 2000;12(3):169.
67. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12th Edition. Wiley, 2015.
68. Vasudev K, Macritchie K, Geddes J, Watson S, Young A. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003384.pub2]
69. Vasudev A, Macritchie K, Rao SNK, Geddes J, Young AH. Tiagabine in the treatment of acute affective episodes in bipolar disorder. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD004694.pub3]
70. Vieta E, Gilabert A, Rodriguez A, Garcia-Castrillon A, Luna MJ, Arrufat F, et al. Topiramate as 'add-on' therapy in refractory bipolar disorder. Acta Neuropsychiatrica 2000;12(3):173.
71. Vieta E, Sanchez-Moerno J, Goikolea JM, Torrent C, Benbarre A, Colom F, et al. Adjunctive topiramate in bipolar II disorder. World Journal of Biological Psychiatry 2003;4(4):172-6. [MEDLINE: 14608588]
72. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
73. World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization; published 2008.
74. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity and Related Metabolic Disorders 2004;28(11):1399-410. [MEDLINE: 15486569]
75. Woods TM, Eichner SF, Franks AS. Weight gain mitigation with topiramate in mood disorders. Annals of Pharmacotherapy 2004;38(5):887-91. [MEDLINE: 15039481]
76. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978;133:429-35.
77. Young AH, Geddes JR, Macritchie K, Rao SN, Watson S, Vasudev A. Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004694.pub2]